{"title":"ramucirumab功能化磁脂质体靶向递送索拉非尼和MRI的治疗潜力。","authors":"Ali Pouresmaeili, Abolghasem Abbasi Kajani","doi":"10.1016/j.xphs.2026.104402","DOIUrl":null,"url":null,"abstract":"<div><div>Development of theranostic nanoplatforms capable of the controlled and targeted delivery of anticancer agents and simultaneous bioimaging has attracted great attention as an exciting and frontier research field. Here, the sorafenib loaded magnetoliposomes (S-MLPs) were synthesized and targeted individually, with a specific aptamer (AS-MLPs) and the ramucirumab antibody (RS-MLPs) against the vascular endothelial growth factor receptor 2 (VEGFR2). The physicochemical characterization revealed the synthesis of high colloidal and monodisperse S-MLPs with an average hydrodynamic size of 147 nm and a zeta potential value of -26.4 mV. The <em>in vitro</em> release study showed a linear release profile for sorafenib with 66.47% cumulative release during 96 h. The anticancer activity of S-MLPs was studied <em>in vitro</em> using the MTT assay, flow cytometry study of apoptosis and necrosis, and the gene expression analysis using real-time PCR and ELISA. The theranostic potential of S-MLPs was also confirmed by the MRI and CAM assay, <em>in vivo</em>. The results demonstrated the lowest cell viabilities of 69.54 and 54.19% after exposure of HepG2 cells to 100 μg mL<sup>−1</sup> of AS-MLPs and RS-MLPs, respectively. Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL<sup>−1</sup>. The R2 relaxation value of 57.262 mM<sup>−1</sup> s<sup>−1</sup> obtained for the MLPs, indicating their high potential for clinical cancer management.</div></div>","PeriodicalId":16741,"journal":{"name":"Journal of pharmaceutical sciences","volume":"115 9","pages":"Article 104402"},"PeriodicalIF":3.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI\",\"authors\":\"Ali Pouresmaeili, Abolghasem Abbasi Kajani\",\"doi\":\"10.1016/j.xphs.2026.104402\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Development of theranostic nanoplatforms capable of the controlled and targeted delivery of anticancer agents and simultaneous bioimaging has attracted great attention as an exciting and frontier research field. Here, the sorafenib loaded magnetoliposomes (S-MLPs) were synthesized and targeted individually, with a specific aptamer (AS-MLPs) and the ramucirumab antibody (RS-MLPs) against the vascular endothelial growth factor receptor 2 (VEGFR2). The physicochemical characterization revealed the synthesis of high colloidal and monodisperse S-MLPs with an average hydrodynamic size of 147 nm and a zeta potential value of -26.4 mV. The <em>in vitro</em> release study showed a linear release profile for sorafenib with 66.47% cumulative release during 96 h. The anticancer activity of S-MLPs was studied <em>in vitro</em> using the MTT assay, flow cytometry study of apoptosis and necrosis, and the gene expression analysis using real-time PCR and ELISA. The theranostic potential of S-MLPs was also confirmed by the MRI and CAM assay, <em>in vivo</em>. The results demonstrated the lowest cell viabilities of 69.54 and 54.19% after exposure of HepG2 cells to 100 μg mL<sup>−1</sup> of AS-MLPs and RS-MLPs, respectively. Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL<sup>−1</sup>. The R2 relaxation value of 57.262 mM<sup>−1</sup> s<sup>−1</sup> obtained for the MLPs, indicating their high potential for clinical cancer management.</div></div>\",\"PeriodicalId\":16741,\"journal\":{\"name\":\"Journal of pharmaceutical sciences\",\"volume\":\"115 9\",\"pages\":\"Article 104402\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2026-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022354926002510\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022354926002510","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI
Development of theranostic nanoplatforms capable of the controlled and targeted delivery of anticancer agents and simultaneous bioimaging has attracted great attention as an exciting and frontier research field. Here, the sorafenib loaded magnetoliposomes (S-MLPs) were synthesized and targeted individually, with a specific aptamer (AS-MLPs) and the ramucirumab antibody (RS-MLPs) against the vascular endothelial growth factor receptor 2 (VEGFR2). The physicochemical characterization revealed the synthesis of high colloidal and monodisperse S-MLPs with an average hydrodynamic size of 147 nm and a zeta potential value of -26.4 mV. The in vitro release study showed a linear release profile for sorafenib with 66.47% cumulative release during 96 h. The anticancer activity of S-MLPs was studied in vitro using the MTT assay, flow cytometry study of apoptosis and necrosis, and the gene expression analysis using real-time PCR and ELISA. The theranostic potential of S-MLPs was also confirmed by the MRI and CAM assay, in vivo. The results demonstrated the lowest cell viabilities of 69.54 and 54.19% after exposure of HepG2 cells to 100 μg mL−1 of AS-MLPs and RS-MLPs, respectively. Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL−1. The R2 relaxation value of 57.262 mM−1 s−1 obtained for the MLPs, indicating their high potential for clinical cancer management.
期刊介绍:
The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.